Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Last updated: July 31, 2023
Sponsor: WeiWei Xiao
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rectal Cancer

Colon Cancer; Rectal Cancer

Adenocarcinoma

Treatment

MRD detection

Clinical Study ID

NCT05969938
B2023-239-01
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the prognosis of patients. In this prospective study, 50 patients with stage II-III rectal cancer who are planing to receive neoadjuvant chemoradiotherapy will be enrolled. The tumor tissue will be collected by colonoscopy before treatment and blood samples will be collected before treatment and during treatment.The whole blood samples will receive MRD detection. The change rate and clearance rate of MRD during treatment will be calculated, and will be associated with imaging efficacy evaluation, pathological efficacy evaluation,and prognosis, to determine the performance of MRD in predicting and judging the efficacy of neoadjuvant chemoradiotherapy and postoperative recurrence of rectal cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria: 1. Age 18-75 2. Rectal adenocarcinoma confirmed by pathology 3. The clinical stage is II-III. 4. Neoadjuvant chemoradiotherapy + radical surgery is planned ( cCR patients can chooseto wait for observation ). 5. ECOG 0-1; 6. No distant metastasis ; 7. Main organ function is normal ; 8. signed informed consent and willing to accept long-term follow-up； 9. No anti-tumor treatment was received within 4 weeks before baseline sampling ; 10. Adequate ' colonoscopy ' tumor tissue samples can be provided for MRD customization,and sufficient whole blood samples need to be provided for baseline MRD detection.

Exclusion

Exclusion Criteria:

  1. unable to provide sufficient tissue / blood samples to meet the research needs ;
  2. received radiotherapy, chemotherapy, or other targeted or immunotherapy beforeenrollment ;
  3. Patients did not receive neoadjuvant therapy according to the original plan ;
  4. Patients refused to accept genetic testing. -

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: MRD detection
Phase:
Study Start date:
June 21, 2023
Estimated Completion Date:
August 31, 2024

Study Description

This study is a prospective, observational study. It is expected to enroll 50 patients with newly diagnosed stage II-III rectal cancer.Before neoadjuvant chemoradiotherapy, tumor tissue will be collected by colonoscopy biopsy for WES and customized panel design, and peripheral blood samples will be collected for baseline MRD detection ( MRD1 ) and during neoadjuvant concurrent chemoradiotherapy ( MRD2-6 ) .Peripheral blood sample will be collected 3-4 weeks after radical surgery ( MRD7 ). For patients who achieved cCR after the end of neoadjuvant therapy and adopted the W & W ( watch and wait ) strategy, the sampling time point was 3 months after the start of watching and waiting ( MRD7 ).

Connect with a study center

  • WeiWei Xiao

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.